Characterization of antidepressant-like effects of p-synephrine stereoisomers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, KW | - |
dc.contributor.author | Kim, HD | - |
dc.contributor.author | Jung, JS | - |
dc.contributor.author | Woo, RS | - |
dc.contributor.author | Kim, HS | - |
dc.contributor.author | Suh, HW | - |
dc.contributor.author | Kim, YH | - |
dc.contributor.author | Song, DK | - |
dc.date.available | 2021-02-22T11:34:31Z | - |
dc.date.issued | 2001-07 | - |
dc.identifier.issn | 0028-1298 | - |
dc.identifier.issn | 1432-1912 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/10439 | - |
dc.description.abstract | We previously reported that p-synephrine has antidepressant-like activity in the murine models of forced swimming and tail suspension. In the present study, we characterized antidepressant-like effects of p-synephrine stereoisomers in both in vivo and in vitro systems. In the tail suspension test, S-(+)-p-synephrine (3 mg/kg, p.o.) reduced the duration of immobility, while R-(-)-p-synephrine (0.3-3 mg/kg, p.o.) had no effect. S-(+)-p-synephrine (0.3, 1 and 3 mg/kg, p.o.) and R-(-)-p-synephrine (1 mg/kg and 3 mg/kg, p.o.) significantly reversed the reserpine (2.5 mg/kg, i.p.)-induced hypothermia. S-(+)-p-synephrine was more effective than R-(-)-p-synephrine in inhibition of both [H-3]noradrenaline uptake in rat cerebral cortical slices (maximal inhibition 85.7 +/-7.8% vs. 59.8 +/-4.3%; EC50 5.8 +/-0.7 muM vs. 13.5 +/-1.2 muM) and [H-3]nisoxetine binding (K-i 4.5 +/-0.5 muM vs. 8.2 +/-0.7 muM). In contrast, R-(-)-p-synephrine was more effective than S-(+)-p-synephrine in stimulation of [H-3]noradrenaline release from rat cerebral cortical slices (maximal stimulation 23.9 +/-1.8% vs. 20.1 +/-1.7%; EC50 8.2 +/-0.6 muM vs. EC50 12.3 +/-0.9 muM). The stimulatory effect of R-(-)-p-synephrine on [H-3]noradrenaline release was inhibited by nisoxetine (100 nM), but tetrodotoxin (1 muM) and elimination of extracellular calcium had no effect. It is suggested that S-(+)-p-synephrine has more effective antidepressant-like activity than R-(-)-p-synephrine. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER-VERLAG | - |
dc.title | Characterization of antidepressant-like effects of p-synephrine stereoisomers | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s002100100416 | - |
dc.identifier.scopusid | 2-s2.0-0034945029 | - |
dc.identifier.wosid | 000169533600004 | - |
dc.identifier.bibliographicCitation | NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, v.364, no.1, pp 21 - 26 | - |
dc.citation.title | NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | - |
dc.citation.volume | 364 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 21 | - |
dc.citation.endPage | 26 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ADRENOCEPTORS | - |
dc.subject.keywordPlus | OCTOPAMINE | - |
dc.subject.keywordAuthor | S-(+)-p-synephrine | - |
dc.subject.keywordAuthor | R-(-)-p-synephrine | - |
dc.subject.keywordAuthor | antidepressants | - |
dc.subject.keywordAuthor | tail suspension test | - |
dc.subject.keywordAuthor | reserpine | - |
dc.subject.keywordAuthor | [H-3]noradrenaline uptake | - |
dc.subject.keywordAuthor | [H-3]noradrenaline release | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.